Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRDF Cardiff Oncology Inc
- Stocks
- Healthcare
- NASDAQ: CRDF
Price (delayed)
$2.75
Market cap
$182.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.92
Enterprise value
$160.21M
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to
Highlights
Cardiff Oncology's debt has decreased by 32% YoY and by 11% QoQ
The equity rose by 16% year-on-year but it has declined by 15% since the previous quarter
The quick ratio has contracted by 12% from the previous quarter but it has grown by 6% YoY
The net income has declined by 21% year-on-year and by 8% since the previous quarter
Cardiff Oncology's revenue has decreased by 14% from the previous quarter and by 3.6% YoY
Key stats
What are the main financial stats of CRDF
Market
Valuations
Earnings
Shares outstanding
66.53M
Market cap
$182.95M
Enterprise value
$160.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.58
Price to sales (P/S)
311.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
272.46
Revenue
$588,000
Gross profit
$588,000
Operating income
-$52.1M
Net income
-$48.85M
EBIT
-$48.85M
EBITDA
-$48.32M
Free cash flow
-$42.75M
Per share
Balance sheet
Liquidity
EPS
-$0.92
EPS diluted
-$0.92
Free cash flow per share
-$0.64
Book value per share
$1.07
Revenue per share
$0.01
TBVPS
$1.27
Total assets
$84.81M
Total liabilities
$13.93M
Debt
$1.36M
Equity
$70.88M
Working capital
$69.42M
Debt to equity
0.02
Current ratio
6.22
Quick ratio
6.04
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
-8,218.4%
Gross margin
100%
Net margin
-8,308.5%
Operating margin
-8,860.5%
Return on assets
-62.9%
Return on equity
-76.5%
Return on invested capital
-129%
Return on capital employed
-68.3%
Return on sales
-8,308.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRDF stock price
How has the Cardiff Oncology stock price performed over time
Intraday
3.38%
1 week
2.61%
1 month
11.34%
1 year
-18.88%
YTD
-36.64%
QTD
-12.42%
Financial performance
How have Cardiff Oncology's revenue and profit performed over time
Revenue
$588,000
Gross profit
$588,000
Operating income
-$52.1M
Net income
-$48.85M
Gross margin
100%
Net margin
-8,308.5%
Cardiff Oncology's net margin has decreased by 26% YoY and by 25% QoQ
The operating margin has declined by 24% since the previous quarter and by 22% year-on-year
The net income has declined by 21% year-on-year and by 8% since the previous quarter
CRDF's operating income is down by 18% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does CRDF's price correlate with its fundamentals
Growth
What is Cardiff Oncology's growth rate over time
Valuation
What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
2.58
P/S
311.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
272.46
Cardiff Oncology's EPS has increased by 3.2% QoQ but it has decreased by 2.2% YoY
The equity rose by 16% year-on-year but it has declined by 15% since the previous quarter
The stock's price to book (P/B) is 12% more than its 5-year quarterly average of 2.3 and 3.2% more than its last 4 quarters average of 2.5
The P/S is 26% more than the last 4 quarters average of 247.3 but 24% less than the 5-year quarterly average of 407.8
Cardiff Oncology's revenue has decreased by 14% from the previous quarter and by 3.6% YoY
Efficiency
How efficient is Cardiff Oncology business performance
The company's return on invested capital has shrunk by 89% YoY and by 5% QoQ
Cardiff Oncology's return on equity has decreased by 40% YoY and by 3.4% QoQ
CRDF's return on assets is down by 34% year-on-year and by 3.8% since the previous quarter
Cardiff Oncology's return on sales has decreased by 26% YoY and by 25% QoQ
Dividends
What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRDF.
Financial health
How did Cardiff Oncology financials performed over time
Cardiff Oncology's total assets has increased by 15% YoY but it has decreased by 13% QoQ
The quick ratio has contracted by 12% from the previous quarter but it has grown by 6% YoY
Cardiff Oncology's debt is 98% lower than its equity
The debt to equity has contracted by 33% YoY
Cardiff Oncology's debt has decreased by 32% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.